|
Jul 27
|
Galapagos Second Quarter 2025 Earnings: Misses Expectations
|
|
Jul 23
|
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
|
|
Jul 23
|
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
|
|
Jul 23
|
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
|
|
Jun 12
|
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
|
|
May 14
|
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
|
|
May 13
|
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
|
|
Feb 14
|
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
|
|
Feb 12
|
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
|
|
Feb 12
|
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now
|